- Home
- DCI vs PCVX Comparison
DCI vs PCVX Comparison
Compare DCI & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DCI | PCVX |
|---|---|---|
| Founded | 1915 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pollution Control Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7B | 9.0B |
| IPO Year | 2005 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DCI | PCVX |
|---|---|---|
| Price | $87.81 | $60.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $99.00 | $88.25 |
| AVG Volume (30 Days) | 469.8K | ★ 1.1M |
| Earning Date | 06-02-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.39% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.75 | N/A |
| Revenue | ★ $2,844,900,000.00 | N/A |
| Revenue This Year | $4.58 | N/A |
| Revenue Next Year | $5.18 | N/A |
| P/E Ratio | $49.32 | ★ N/A |
| Revenue Growth | ★ 4.05 | N/A |
| 52 Week Low | $64.25 | $28.09 |
| 52 Week High | $112.84 | $65.00 |
Technical Indicators
Market Signals| Indicator | DCI | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 47.91 | 53.99 |
| Support Level | $86.41 | $52.04 |
| Resistance Level | $88.70 | $65.00 |
| Average True Range (ATR) | 1.83 | 2.16 |
| MACD | 0.36 | -0.08 |
| Stochastic Oscillator | 59.44 | 51.54 |
Price Performance
Historical ComparisonAbout DCI Donaldson Company Inc.
Donaldson is a leading manufacturer of filtration systems and replacement parts (including air filtration systems, liquid filtration systems, and dust, fume, and mist collectors). The company serves a diverse range of end markets, including construction, mining, agriculture, truck, and industrial. Its business is organized into three segments: mobile solutions, industrial solutions, and life sciences. Donaldson generated approximately $3.7 billion in revenue in its fiscal 2025.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.